Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Gyre Therapeutics (GYRE) over the last 14 years, with Q3 2025 value amounting to -$1000.0.

  • Gyre Therapeutics' Other Operating Expenses changed N/A to -$1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year increase of 16414.63%. This contributed to the annual value of $61.5 million for FY2024, which is 236709.7% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Other Operating Expenses of -$1000.0 as of Q3 2025.
  • Gyre Therapeutics' Other Operating Expenses' 5-year high stood at $57.2 million during Q2 2022, with a 5-year trough of -$2.2 million in Q4 2023.
  • In the last 5 years, Gyre Therapeutics' Other Operating Expenses had a median value of $1.3 million in 2021 and averaged $6.9 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 492589.99% in 2022, then tumbled by 360338.98% in 2023.
  • Gyre Therapeutics' Other Operating Expenses (Quarter) stood at $2.5 million in 2021, then plummeted by 102.4% to -$59000.0 in 2022, then plummeted by 3603.39% to -$2.2 million in 2023, then surged by 925.22% to $18.0 million in 2024, then crashed by 100.01% to -$1000.0 in 2025.
  • Its Other Operating Expenses stands at -$1000.0 for Q3 2025, versus -$1000.0 for Q2 2025 and $11.7 million for Q1 2025.